Programmed Cell Death Protein 1-Interleukin-2 Bispecific Agents for Cancer Therapy.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Programmed Cell Death Protein 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) inhibitors offer cancer immunotherapy benefits but face limitations like low response rates and drug resistance.
• Interleukin-2 (IL-2) is a T-cell activator but its clinical use is restricted by severe toxicity and regulatory T-cell (Treg) activation.

Purpose of the Study:

• To review the progress of PD1-IL2 bispecific drugs, which integrate PD-1 blockade and engineered IL-2 variants (IL-2v).
• To explore their synergistic mechanisms, molecular designs, and potential to overcome limitations of current immunotherapies.

Main Methods:

• Review of preclinical and clinical data on PD1-IL2 bispecific drugs, including specific examples like IBI363.
• Analysis of synergistic signaling pathways involving PD-1/PD-L1 and IL-2.
• Examination of molecular designs such as βγ-biased and α-biased IL-2 variants and 'cis delivery' strategies.

Main Results:

• PD1-IL2 bispecific drugs demonstrate encouraging anti-tumor activity and improved safety profiles in advanced cancers.
• These agents show potential benefits for patients resistant to PD-1/PD-L1 inhibitors.
• Early data suggests precise regulation of the tumor microenvironment immunity.

Conclusions:

• PD1-IL2 bispecific drugs represent a promising advancement in tumor immunotherapy, offering targeted activation and overcoming existing treatment challenges.
• Further research is needed to clarify mechanisms, address drug resistance, and ensure long-term safety.
• Optimized molecular design, combination therapies, and predictive biomarkers are key for future development and broader patient application.